Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wayne Tam

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Haematologica|December 24, 2025
Isolated <i>KRAS</i> and <i>NRAS</i> mutations in adults with monocytosis and/or cytopenia(s)Sa A Wang, Chi Young Ok, Harrison K Tsai, et al.
Blood Advances|November 18, 2022
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potentialYong Li, Zijun Y Xu-Monette, Jeremy Abramson, et al.
Haematologica|October 15, 2020
Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohortJohanne M Holst, Trine L Plesner, Martin B Pedersen, et al.
Leukemia Research|November 4, 2022
NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotypeMaximiliano Ramia de Cap, Leo P Wu, German A Pihan, et al.
Blood Cancer Journal|February 2, 2022
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithmsMaher Albitar, Hong Zhang, Andre Goy, et al.
Nature Medicine|September 15, 2015
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma developmentAna Ortega-Molina, Isaac W Boss, Andres Canela, et al.
Leukemia & Lymphoma|March 24, 2023
Myeloid sarcoma with <i>NPM1</i> mutation may be clinically and genetically distinct from AML with <i>NPM1</i> mutation: a study from the Bone Marrow Pathology GroupMaximiliano Ramia de Cap, Leo P Wu, Christian Hirt, et al.
Nature Cancer|February 11, 2021
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencingSara Parsa, Ana Ortega-Molina, Hsia-Yuan Ying, et al.
Molecular Cancer Research : MCR|November 6, 2020
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted AgentsManman Deng, Zijun Y Xu-Monette, Lan V Pham, et al.
Blood Advances|July 30, 2020
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCLZijun Y Xu-Monette, Hongwei Zhang, Feng Zhu, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Haematologica|December 24, 2025
Isolated <i>KRAS</i> and <i>NRAS</i> mutations in adults with monocytosis and/or cytopenia(s)Sa A Wang, Chi Young Ok, Harrison K Tsai, et al.
Blood Advances|November 18, 2022
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potentialYong Li, Zijun Y Xu-Monette, Jeremy Abramson, et al.
Haematologica|October 15, 2020
Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohortJohanne M Holst, Trine L Plesner, Martin B Pedersen, et al.
Leukemia Research|November 4, 2022
NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotypeMaximiliano Ramia de Cap, Leo P Wu, German A Pihan, et al.
Blood Cancer Journal|February 2, 2022
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithmsMaher Albitar, Hong Zhang, Andre Goy, et al.
Nature Medicine|September 15, 2015
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma developmentAna Ortega-Molina, Isaac W Boss, Andres Canela, et al.
Leukemia & Lymphoma|March 24, 2023
Myeloid sarcoma with <i>NPM1</i> mutation may be clinically and genetically distinct from AML with <i>NPM1</i> mutation: a study from the Bone Marrow Pathology GroupMaximiliano Ramia de Cap, Leo P Wu, Christian Hirt, et al.
Nature Cancer|February 11, 2021
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencingSara Parsa, Ana Ortega-Molina, Hsia-Yuan Ying, et al.
Molecular Cancer Research : MCR|November 6, 2020
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted AgentsManman Deng, Zijun Y Xu-Monette, Lan V Pham, et al.
Blood Advances|July 30, 2020
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCLZijun Y Xu-Monette, Hongwei Zhang, Feng Zhu, et al.
Pageof 14